Liminatus Pharma, Inc. (LIMN)
| Market Cap | 6.31M -92.1% |
| Revenue (ttm) | n/a |
| Net Income | -2.27M |
| EPS | -0.02 |
| Shares Out | 27.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,622,250 |
| Open | 0.2416 |
| Previous Close | 0.2380 |
| Day's Range | 0.2313 - 0.2490 |
| 52-Week Range | 0.2100 - 33.6600 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 1, 2026 |
About LIMN
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPα blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Financial Performance
Financial StatementsNews
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology company developing next-generation CD47-b...
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today ...
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic Value Liminatus Id...
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed Strategic Internal Review initiated for treasur...
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing paths Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backe...
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy
LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies...